Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 423

1.

Synthesis, conformational preferences, and biological activity of conformational analogues of the microtubule-stabilizing agents, (-)-zampanolide and (-)-dactylolide.

Henry JL, Wilson MR, Mulligan MP, Quinn TR, Sackett DL, Taylor RE.

Medchemcomm. 2019 Apr 9;10(5):800-805. doi: 10.1039/c9md00164f. eCollection 2019 May 1.

PMID:
31191870
2.

All tubulins are not alike: Heterodimer dissociation differs among different biological sources.

Montecinos-Franjola F, Chaturvedi SK, Schuck P, Sackett DL.

J Biol Chem. 2019 Jun 28;294(26):10315-10324. doi: 10.1074/jbc.RA119.007973. Epub 2019 May 20.

PMID:
31110044
3.

A simple empirical algorithm for optimising depletion power and resolution for dye and system specific STED imaging.

Combs CA, Sackett DL, Knutson JR.

J Microsc. 2019 Jun;274(3):168-176. doi: 10.1111/jmi.12795. Epub 2019 May 9.

PMID:
31012103
4.

Targeting mitochondrial hexokinases increases efficacy of histone deacetylase inhibitors in solid tumor models.

McDonald AJ, Curt KM, Patel RP, Kozlowski H, Sackett DL, Robey RW, Gottesman MM, Bates SE.

Exp Cell Res. 2019 Feb 15;375(2):106-112. doi: 10.1016/j.yexcr.2018.12.012. Epub 2018 Dec 21.

PMID:
30579954
5.

Design and 22-step synthesis of highly potent D-ring modified and linker-equipped analogs of spongistatin 1.

Suen LM, Tekle-Smith MA, Williamson KS, Infantine JR, Reznik SK, Tanis PS, Casselman TD, Sackett DL, Leighton JL.

Nat Commun. 2018 Nov 9;9(1):4710. doi: 10.1038/s41467-018-07259-x.

6.

Intracellular oxygen mapping using a myoglobin-mCherry probe with fluorescence lifetime imaging.

Penjweini R, Andreoni A, Rosales T, Kim J, Brenner MD, Sackett DL, Chung JH, Knutson JR.

J Biomed Opt. 2018 Oct;23(10):1-14. doi: 10.1117/1.JBO.23.10.107001.

7.

Using in vivo fluorescence lifetime imaging to detect HER2-positive tumors.

Ardeshirpour Y, Sackett DL, Knutson JR, Gandjbakhche AH.

EJNMMI Res. 2018 Apr 4;8(1):26. doi: 10.1186/s13550-018-0384-6.

8.

Colchicine: an ancient drug with novel applications.

Dasgeb B, Kornreich D, McGuinn K, Okon L, Brownell I, Sackett DL.

Br J Dermatol. 2018 Feb;178(2):350-356. doi: 10.1111/bjd.15896. Epub 2018 Jan 3. Review.

9.

Synthesis and Evaluation of a Linkable Functional Group-Equipped Analogue of the Epothilones.

Foley CN, Chen LA, Sackett DL, Leighton JL.

ACS Med Chem Lett. 2017 May 1;8(7):701-704. doi: 10.1021/acsmedchemlett.7b00131. eCollection 2017 Jul 13.

10.

Benzocoumarin Hydrazine: A Large Stokes Shift Fluorogenic Sensor for Detecting Carbonyls in Isolated Biomolecules and in Live Cells.

Mukherjee K, Chio TI, Gu H, Banerjee A, Sorrentino AM, Sackett DL, Bane SL.

ACS Sens. 2017 Jan 27;2(1):128-134. doi: 10.1021/acssensors.6b00616. Epub 2017 Jan 18.

PMID:
28722432
11.

Synthesis and Biological Evaluation of 7-Deoxy-Epothilone Analogues.

Woods LM, Arico JW, Frein JD, Sackett DL, Taylor RE.

Int J Mol Sci. 2017 Mar 17;18(3). pii: E648. doi: 10.3390/ijms18030648.

12.

Tubulin Dimer Reversible Dissociation: AFFINITY, KINETICS, AND DEMONSTRATION OF A STABLE MONOMER.

Montecinos-Franjola F, Schuck P, Sackett DL.

J Biol Chem. 2016 Apr 22;291(17):9281-94. doi: 10.1074/jbc.M115.699728. Epub 2016 Mar 2.

13.

Katanin Severing and Binding Microtubules Are Inhibited by Tubulin Carboxy Tails.

Bailey ME, Sackett DL, Ross JL.

Biophys J. 2015 Dec 15;109(12):2546-2561. doi: 10.1016/j.bpj.2015.11.011.

14.

A "methyl extension" strategy for polyketide natural product linker site validation and its application to dictyostatin.

Ho S, Sackett DL, Leighton JL.

J Am Chem Soc. 2015 Nov 11;137(44):14047-50. doi: 10.1021/jacs.5b09869. Epub 2015 Nov 3.

15.

Tubulin tail sequences and post-translational modifications regulate closure of mitochondrial voltage-dependent anion channel (VDAC).

Sheldon KL, Gurnev PA, Bezrukov SM, Sackett DL.

J Biol Chem. 2015 Oct 30;290(44):26784-9. doi: 10.1074/jbc.M115.678854. Epub 2015 Aug 25.

16.

Why Did the Randomized Clinical Trial Become the Primary Focus of My Career?

Sackett DL.

Value Health. 2015 Jul;18(5):550-2. doi: 10.1016/j.jval.2015.04.001. Epub 2015 Jun 10. No abstract available.

17.

Clinician trialist rounds: 28. When RCT participants are lost to follow-up. Part 1: Why even a few can matter.

Walsh M, Devereaux PJ, Sackett DL.

Clin Trials. 2015 Oct;12(5):537-9. doi: 10.1177/1740774515597702. Epub 2015 Aug 6. No abstract available.

PMID:
26253052
18.

Detection of oxidative stress-induced carbonylation in live mammalian cells.

Mukherjee K, Chio TI, Sackett DL, Bane SL.

Free Radic Biol Med. 2015 Jul;84:11-21. doi: 10.1016/j.freeradbiomed.2015.03.011. Epub 2015 Mar 20.

19.

STAQ: A route toward low power, multicolor nanoscopy.

Rosales T, Sackett DL, Xu J, Shi ZD, Xu B, Li H, Kaur G, Frohart E, Shenoy N, Cheal SM, Wu H, Dulcey AE, Hu Y, Li C, Lane K, Griffiths GL, Knutson JR.

Microsc Res Tech. 2015 May;78(5):343-55. doi: 10.1002/jemt.22478. Epub 2015 Mar 12.

PMID:
25762506
20.

Clinician-trialist rounds: 27. Sabbaticals. Part 2: I'm taking a sabbatical! How should I prepare for it?

Stelfox HT, Straus SE, Sackett DL.

Clin Trials. 2015 Jun;12(3):287-90. doi: 10.1177/1740774514567970. Epub 2015 Jan 29. No abstract available.

PMID:
25633806
21.

An inexpensive replacement for dry ice in the laboratory.

Ismalaj T, Sackett DL.

Anal Biochem. 2015 Apr 1;474:38-9. doi: 10.1016/j.ab.2015.01.008. Epub 2015 Jan 21.

22.

Clinician-trialist rounds: 26. Sabbaticals. Part 1: should I take a sabbatical?

Straus SE, Sackett DL.

Clin Trials. 2015 Apr;12(2):174-6. doi: 10.1177/1740774514562917. Epub 2014 Dec 5. No abstract available.

PMID:
25480539
23.

Clinician-trialist rounds: 25. Designing an evidence-based introductory graduate course in clinical trials. Part 2: Applying the evidence to your RCT course design.

Norman GR, Sackett DL.

Clin Trials. 2015 Feb;12(1):91-3. doi: 10.1177/1740774514552111. Epub 2014 Oct 1. No abstract available.

PMID:
25278229
24.

Clinician-trialist rounds: 24. Modernizing your introductory graduate course in clinical trials. Part 1: Commonsense meets evidence.

Norman GR, Sackett DL.

Clin Trials. 2014 Dec;11(6):681-4. doi: 10.1177/1740774514542622. Epub 2014 Jul 16. No abstract available.

PMID:
25030023
25.

Multiscale BerEp4 molecular imaging of microtumor phantoms: toward theranostics for basal cell carcinoma.

Dasgeb B, Smirnov AV, Ardeshirpour Y, Sackett DL, Knutson JR, Mehregan D, Gandjbakhche A, Halpern AC.

Mol Imaging. 2014;13. doi: 10.2310/7290.2014.00016.

PMID:
25022347
26.

Clinician-trialist rounds: 23. When an RCT's Data Center Report drowns vital information in seas of data: where's Waldo?

Pogue J, Sackett DL.

Clin Trials. 2014 Oct;11(5):601-4. doi: 10.1177/1740774514534347. Epub 2014 Jun 23. No abstract available.

PMID:
24958742
27.

Clinician-trialist rounds: 22. The presenting complaints, diagnoses, and treatments of mentorships in trouble. Part 2: abuses of power.

Straus SE, Sackett DL.

Clin Trials. 2014 Aug;11(4):508-511. Epub 2014 Apr 7. No abstract available.

PMID:
24711611
28.

Clinician-trialist rounds: 21. The presenting complaints, diagnoses and treatments of mentorships in trouble. Part 1: Dysfunctional mentorship meetings.

Sackett DL.

Clin Trials. 2014 Jun;11(3):376-379. doi: 10.1177/1740774513519877. No abstract available.

PMID:
24563377
29.

Clinician-trialist rounds: 20. Shouldn't 'trialists-in-training' rotate through RCT-clerkships?

Sackett DL.

Clin Trials. 2014 Apr;11(2):263-6. doi: 10.1177/1740774513511716. Epub 2013 Dec 9. No abstract available.

PMID:
24323133
30.

Clinician-trialist rounds: 19. Faux pas or fraud? Identifying centers that have fabricated their data in your multi-center trial.

Pogue J, Sackett DL.

Clin Trials. 2014 Feb;11(1):128-30. doi: 10.1177/1740774513503524. Epub 2013 Oct 3. No abstract available.

PMID:
24096634
31.

Clinician-trialist rounds: 18. Should young (and old!) clinician-trialists perform single-arm Phase II futility trials?

Sackett DL.

Clin Trials. 2013;10(6):987-9. doi: 10.1177/1740774513503523. Epub 2013 Oct 1. No abstract available.

PMID:
24085773
32.

Multiwell stiffness assay for the study of cell responsiveness to cytotoxic drugs.

Zustiak S, Nossal R, Sackett DL.

Biotechnol Bioeng. 2014 Feb;111(2):396-403. doi: 10.1002/bit.25097. Epub 2013 Sep 6.

33.

Measurement of in vitro microtubule polymerization by turbidity and fluorescence.

Mirigian M, Mukherjee K, Bane SL, Sackett DL.

Methods Cell Biol. 2013;115:215-29. doi: 10.1016/B978-0-12-407757-7.00014-1.

PMID:
23973075
34.

Clinician-trialist rounds: 17. Mind your explanatory and pragmatic attitudes! Part 2: How?

Sackett DL.

Clin Trials. 2013 Aug;10(4):633-6. doi: 10.1177/1740774513491339. Epub 2013 Jun 21. No abstract available.

PMID:
23794407
35.

CKAP2 ensures chromosomal stability by maintaining the integrity of microtubule nucleation sites.

Case CM, Sackett DL, Wangsa D, Karpova T, McNally JG, Ried T, Camps J.

PLoS One. 2013 May 30;8(5):e64575. doi: 10.1371/journal.pone.0064575. Print 2013.

36.

Clinician-trialist rounds: 16. Mind your explanatory and pragmatic attitudes! - part 1: what?

Sackett DL.

Clin Trials. 2013;10(3):495-8. doi: 10.1177/1740774513484395. No abstract available.

PMID:
23690096
37.

Six pairs of things to celebrate on International Clinical Trials Day.

Sackett DL.

Trials. 2013 May 20;14:128. doi: 10.1186/1745-6215-14-128.

38.

Clinician-trialist rounds: 15. Ways to advance your career by saying 'no'--part 3: how to say 'no', nicely.

Oxman AD, Sackett DL.

Clin Trials. 2013 Apr;10(2):340-3. doi: 10.1177/1740774513477934. No abstract available.

PMID:
23539113
39.

Tales of how great drugs were brought down by a flawed rationale--response.

Komlodi-Pasztor E, Sackett DL, Fojo T.

Clin Cancer Res. 2013 Mar 1;19(5):1304. doi: 10.1158/1078-0432.CCR-12-2058. Epub 2013 Feb 7. No abstract available.

40.

Clinician-trialist rounds: 14. ways to advance your career by saying 'no' - part 2: when to say 'no', and why.

Oxman AD, Sackett DL.

Clin Trials. 2013 Feb;10(1):181-7. doi: 10.1177/1740774512467238. No abstract available.

PMID:
23345309
41.

Clinician-trialist rounds: 13. Ways to advance your career by saying 'no' - part 1: why to say 'no' (nicely), and saying 'no' to email.

Oxman AD, Sackett DL.

Clin Trials. 2012 Dec;9(6):806-8. doi: 10.1177/1740774512463177. No abstract available.

PMID:
23250947
42.

Clinician-trialist rounds: 12. When your grant gets turned down--part 2: resurrection.

Szatmari P, Sackett DL.

Clin Trials. 2012 Oct;9(5):660-3. doi: 10.1177/1740774512455465. No abstract available.

PMID:
23060324
43.

Fabrication of hydrogels with steep stiffness gradients for studying cell mechanical response.

Sunyer R, Jin AJ, Nossal R, Sackett DL.

PLoS One. 2012;7(10):e46107. doi: 10.1371/journal.pone.0046107. Epub 2012 Oct 4.

44.

Clinician-trialist rounds: 11. When your grant gets turned down--part 1: remorse, anger, and reconciliation.

Szatmari P, Sackett DL.

Clin Trials. 2012 Aug;9(4):447-9. doi: 10.1177/1740774512449701. No abstract available.

PMID:
22923728
45.

Clinician-trialist rounds: 10. Mentoring - part 4: attributes of an effective mentor.

Straus SE, Sackett DL.

Clin Trials. 2012 Jun;9(3):367-9. doi: 10.1177/1740774512440343. No abstract available.

PMID:
22692806
46.

Quantitative scheme for full-field polarization rotating fluorescence microscopy using a liquid crystal variable retarder.

Lesoine JF, Lee JY, Krogmeier JR, Kang H, Clarke ML, Chang R, Sackett DL, Nossal R, Hwang J.

Rev Sci Instrum. 2012 May;83(5):053705. doi: 10.1063/1.4717682.

47.

[What is EBM and what is not?].

Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS.

Neuere Med Wiss Quellen Stud. 2012;22:13-7. German. No abstract available.

PMID:
22530492
48.

Clinician-trialist rounds: 9. Mentoring - part 3: the structure and function of effective mentoring: advice and protection.

Straus SE, Sackett DL.

Clin Trials. 2012 Apr;9(2):272-4. doi: 10.1177/1740774512436615. No abstract available.

PMID:
22496399
49.

Clinician-trialist rounds: 8. Mentoring - part 2: the structure and function of effective mentoring linkage, resources, and academic opportunities.

Straus SE, Sackett DL.

Clin Trials. 2012 Feb;9(1):128-31. doi: 10.1177/1740774511430241. No abstract available.

PMID:
22334471
50.

Inhibitors targeting mitosis: tales of how great drugs against a promising target were brought down by a flawed rationale.

Komlodi-Pasztor E, Sackett DL, Fojo AT.

Clin Cancer Res. 2012 Jan 1;18(1):51-63. doi: 10.1158/1078-0432.CCR-11-0999. Review.

Supplemental Content

Loading ...
Support Center